TY  - JOUR
AU  - Gonzalez Maldonado, Sandra
AU  - Johnson, Theron
AU  - Motsch, Erna
AU  - Delorme, Stefan
AU  - Kaaks, Rudolf
TI  - Can autoantibody tests enhance lung cancer screening?-an evaluation of EarlyCDT®-Lung in context of the German Lung Cancer Screening Intervention Trial (LUSI).
JO  - Translational Lung Cancer Research
VL  - 10
IS  - 1
SN  - 2226-4477
CY  - [S.l.]
M1  - DKFZ-2021-00346
SP  - 233 - 242
PY  - 2021
N1  - #EA:C020#LA:C020#
AB  - Tumor-associated autoantibodies are considered promising markers for early lung cancer detection; so far, however, their capacity to detect cancer has been tested mostly in a clinical context, but not in population screening settings. This study evaluates the early detection accuracy, in terms of sensitivity and specificity, of EarlyCDT®-Lung-a test panel of seven tumor-associated autoantibodies optimized for lung cancer detection-using blood samples originally collected as part of the German Lung Cancer Screening Intervention Trial.The EarlyCDT®-Lung test was performed for all participants with lung cancer detected via low-dose computed tomography and with available blood samples taken at detection, and for 180 retrospectively selected cancer-free participants at the end of follow-up: 90 randomly selected from among all cancer-free participants (baseline controls) and 90 randomly selected from among cancer-free participants with suspicious imaging findings (suspicious nodules controls). Sensitivity and specificity of lung cancer detection were estimated in the case group and the two control groups, respectively.In the case group, the test panel showed a sensitivity of only 13.0
KW  - Lung cancer screening (Other)
KW  - autoantibody test (Other)
KW  - early detection (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:33569307
C2  - pmc:PMC7867751
DO  - DOI:10.21037/tlcr-20-727
UR  - https://inrepo02.dkfz.de/record/167442
ER  -